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The pleiotropic second messenger 3′-5′-cyclic adenosine monophosphate (cAMP) mediates the catecholaminergic 
control on heart rate and contractility and, at the same time, is 
responsible for the functional response of the heart to a wide 
variety of other hormones and neurotransmitters. cAMP sig-
naling is also central to the pathogenesis of several conditions, 
including cardiac hypertrophy, arrhythmia, and heart failure.1 
An important advance in cardiac adrenergic signal transduc-
tion is the realization in the past decade that the high fidelity 
with which cAMP mediates a plethora of different functions 
relies on the spatial segregation of the molecular components 
of this signaling pathway within subcellular microdomains.2,3 
The hormonal specificity of cAMP action4 results from the 
generation of distinct pools of the second messenger, which 
in turn mediates different functional outcomes via activation 
of different subsets of the cAMP effector protein kinase A 
(PKA).5,6 PKA is a holotetrameric enzyme composed of a di-
mer of regulatory (R) and 2 catalytic (C) subunits. In the heart, 
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Rationale: Chronic elevation of 3′-5′-cyclic adenosine monophosphate (cAMP) levels has been associated with 
cardiac remodeling and cardiac hypertrophy. However, enhancement of particular aspects of cAMP/protein 
kinase A signaling seems to be beneficial for the failing heart. cAMP is a pleiotropic second messenger with the 
ability to generate multiple functional outcomes in response to different extracellular stimuli with strict fidelity, a 
feature that relies on the spatial segregation of the cAMP pathway components in signaling microdomains.
Objective: How individual cAMP microdomains affect cardiac pathophysiology remains largely to be established. 
The cAMP-degrading enzymes phosphodiesterases (PDEs) play a key role in shaping local changes in cAMP. Here 
we investigated the effect of specific inhibition of selected PDEs on cardiac myocyte hypertrophic growth.
Methods and Results: Using pharmacological and genetic manipulation of PDE activity, we found that the rise 
in cAMP resulting from inhibition of PDE3 and PDE4 induces hypertrophy, whereas increasing cAMP levels 
via PDE2 inhibition is antihypertrophic. By real-time imaging of cAMP levels in intact myocytes and selective 
displacement of protein kinase A isoforms, we demonstrate that the antihypertrophic effect of PDE2 inhibition 
involves the generation of a local pool of cAMP and activation of a protein kinase A type II subset, leading to 
phosphorylation of the nuclear factor of activated T cells.
Conclusions: Different cAMP pools have opposing effects on cardiac myocyte cell size. PDE2 emerges as a novel 
key regulator of cardiac hypertrophy in vitro and in vivo, and its inhibition may have therapeutic applications.  
(Circ Res. 2015;117:707-719. DOI: 10.1161/CIRCRESAHA.114.305892.)
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2 PKA isoforms are expressed, PKA type I and PKA type II, 
which differ in their R subunit. In cardiac myocytes, PKA is 
largely localized to different subcellular compartments6 via 
binding to a family of scaffolding proteins known as A kinase 
anchoring proteins (AKAPs).7 Apart from their common abil-
ity to anchor PKA, AKAPs show a high degree of structural 
variability, which allows for different subcellular localization 
and binding to a variety of signaling components. As a re-
sult, AKAPs serve as signaling centers, where specific binding 
partners are organized for a particular task. Localization of 
PKA is achieved through the interaction of the amino-termi-
nal dimerization/docking domain of the R subunits8 with the 
AKAP and serves to anchor PKA in proximity to selected tar-
gets, thus favoring their preferential phosphorylation.9–11 The 
AKAP-dimerization/docking interaction is also responsible 
for differential targeting of the 2 PKA isoforms, with different 
AKAPs showing different specificity of binding for RI and 
RII12 as a consequence of differences within the docking in-
terface in R.13
The intracellular concentration of cAMP is tightly regu-
lated by the cyclic nucleotide degrading enzymes phospho-
diesterases (PDEs). PDEs are a large superfamily of enzymes 
including 11 families (PDE1–11) with several different genes 
and splice variants generating close to 100 isozymes show-
ing unique kinetic, regulatory, and subcellular localization 
properties.14 PDEs play a pivotal role in shaping local cAMP 
signals by limiting cAMP diffusion beyond a microdomain 
and by regulating cAMP levels within a microdomain. As a 
consequence, inhibition of individual PDE families results in 
a compartmentalized increase in cAMP as shown by studies 
using targeted reporters and real-time imaging of cAMP levels 
in intact myocytes.15,16
We have previously reported that in intact neonatal rat 
ventricular myocytes (NRVMs), PDE2, PDE3, and PDE4 are 
localized at distinct subcellular sites and uniquely modulate 
the cAMP response to individual extracellular stimuli.17,18 In 
NRVM cell lysates, PDE3 and PDE4 account for most of 
the PDE activity, whereas PDE2 is responsible for only a 
minor fraction of cAMP hydrolytic activity.17 However, in 
intact NRVMs, in spite of its low abundance, PDE2 plays 
a major role in the control of the cAMP response to cate-
cholamines,18 an effect that relies on its specific localization 
within the cell.16
Although the concept of compartmentalized cAMP/
PKA signaling in cardiac myocytes is well established and 
the physiological function downstream of individual cAMP 
pools is being elucidated,10,11,19,20 little is known about the 
role of local cAMP pools in the pathogenesis of heart dis-
ease. Catecholamines induce cardiac hypertrophy via mech-
anisms that include activation of β-adrenergic receptors, 
generation of cAMP, and PKA-mediated elevation of intra-
cellular Ca2+.21 Although chronic stimulation of β-adrenergic 
signaling leads to pathological sequelae, enhancement of 
particular aspects of cAMP/PKA signaling benefits the fail-
ing heart,22–24 suggesting that different components of this 
pathway may have different consequences on cardiac hyper-
trophy and failure.
In this study, we investigate the effect on cardiac hyper-
trophy of local manipulation of cAMP levels via selective 
inhibition of individual PDEs. We find that distinct pools of 
cAMP affect cardiac myocyte hypertrophic growth differ-
ently and that inhibition of PDE2, unlike inhibition of PDE3 
or PDE4, results in antihypertrophic effects both in vitro and 
in vivo. We further demonstrate that increased PDE2 activ-
ity is sufficient per se to induce hypertrophy. The antihyper-
trophic effect of PDE2 inhibition relies on a local increase 
in cAMP that enhances PKA-mediated phosphorylation of 
nuclear factor of activated T cells (NFAT) and its consequent 
retention in the cytosol. We conclude that PDE2 regulates a 
pool of cAMP with unique effects on cardiac myocyte hy-
pertrophic growth and identify PDE2 as a potential thera-
peutic target.
Methods
A detailed description of the Materials and Methods is included in the 
Online Data Supplement to this article.
Results
PDE2 Inhibition Counteracts Cardiac Myocyte 
Hypertrophy In Vitro and In Vivo
Treatment of NRVMs with 10 μmol/L norepinephrine for 48 
hours is a well-established in vitro model of cardiac hypertro-
phy25 eliciting the expected hypertrophy markers, including 
increase in cell surface area,3H-leucine incorporation, nuclear 
translocation of NFAT (Figure 1B–1D), and atrial natriuretic 
peptide levels (Online Figure IA). To investigate the effect of 
raising cAMP levels on cardiac myocyte hypertrophy, we treat-
ed NRVMs with different cAMP-raising agents (Figure 1A). 
Activation of adenylyl cyclase with 1 μmol/L forskolin, inhibi-
tion of PDE4 with 10 μmol/L rolipram, and inhibition of PDE3 
with 10 μmol/L cilostamide generated significant hypertrophy 
(Figure 1B–1D). In contrast, inhibition of PDE2 with BAY 
60-7550 (10 μmol/L) did not induce hypertrophy (Figure 1B–
1D), despite generating an increase in cAMP (Figure 1A). The 
unique effect of PDE2 inhibition on cell hypertrophy was also 
apparent in cells co-treated with norepinephrine. When cilo-
stamide and rolipram were administered in combination with 
10 μmol/L norepinephrine, norepinephrine further increased 
cell size compared with inhibitor alone, although no further 
enhancement of hypertrophy was observed compared with 
norepinephrine alone (compare Figure 1B–1D and 1F–1I). 
In contrast, BAY 60-7550 blocked the hypertrophic growth 
induced by norepinephrine (Figure 1F–1I and Online Figure 
IA–IF), despite its potentiation of the norepinephrine-induced 
Nonstandard Abbreviations and Acronyms
AKAP A kinase anchoring protein
ARVM adult rat ventricular myocyte
cAMP 3′-5′-cyclic adenosine monophosphate
NFAT nuclear factor of activated T cells
NRVM neonatal rat ventricular myocyte
PDE phosphodiesterase
PKA protein kinase A
TAC transverse aorta constriction
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cAMP response (Figure 1E). The antihypertrophic effect 
of BAY 60-7550 was confirmed at 50 nmol/L of inhibitor 
(Online Figure IB). Similar results were found with erythro-
9-(2-hydroxy-3-nonyl)adenine, another selective PDE2 in-
hibitor (Online Figure IC), in cardiomyocytes from neonatal 
mice (Online Figure ID) and in adult rat ventricular myocytes 
(ARVMs) (Online Figure IE and IF). Similar effects on cell 
size (Figure 1J) and NFAT-green fluorescent protein (GFP) 
nuclear translocation (Figure 1K) were found when PDE2 ex-
pression was knocked down using the small interfering RNA 
Figure 1. Effect of phosphodiesterase 2 (PDE2) inhibition on cardiac myocyte hypertrophy in vitro. A, cAMP increase induced 
by 1 nmol/L norepinephrine (NE), 10 nmol/L isoproterenol (ISO), 1 μmol/L forskolin, 10 μmol/L rolipram, 10 μmol/L cilostamide, or 10 
μmol/L BAY 60-7550 measured in neonatal rat ventricular myocytes (NRVMs) using real-time fluorescence resonance energy transfer 
(FRET) imaging (n≥4 cells). B, Cell surface area of NRVMs treated for 48 hours with NE (10 μmol/L), ISO (10 μmol/L), forskolin (1 μmol/L), 
rolipram (10 μmol/L), cilostamide (10 μmol/L), and BAY 60-7550 (10 μmol/L) or untreated control. n≥32 cells. [3H] leucine incorporation 
(n≥16 independent experiments; C) and nuclear factor of activated T cells (NFAT)-green fluorescent protein (GFP) nuclear translocation 
measurements (minimum of 3 independent experiments; D) calculated for untreated NRVMs or NRVMs treated as indicated. E, FRET 
measurements of cAMP levels in NRVMs on stimulation with NE (1 nmol/L) and NE in combination with 10 μmol/L rolipram, 10 μmol/L 
cilostamide, or 10 μmol/L BAY 60-7550. Cell surface area (n≥44 cells; F), [3H] leucine incorporation (n≥27 independent experiments; 
G), normalized protein content (H) and NFAT-GFP nuclear translocation (I) measured in NRVMs untreated or treated for 48 hours as 
indicated. Cell surface area (minimum of n=128 cells per condition; J) and NFAT-GFP nuclear translocation (minimum of 5 independent 
experiments; K) for control, NE (10 μmol/L)-treated NRVMs, and NRVMs treated with NE (10 μmol/L) and transfected either with siPDE2 
(small interference RNA for PDE2) or with the control oligo siGLO Red. L, Cell surface area of NRVMs treated for 48 hours as indicated; 
phenylephrine (PE; 1 μmol/L), BAY 60-7550 (10 μmol/L); n≥135 cells. All data represent mean±SEM. One-way ANOVA and Tukey’s 
multiple comparison tests were performed. Pixel size =0.1075 μm. *P≤0.05; **P≤0.01; ***P≤0.005; ns=not significant.
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sequence siPDE2 (small interference RNA for PDE2).16 The 
specificity of the small interfering RNA effect was confirmed 
by rescue experiments (Online Figure II). BAY 60-7550 
also blocked the hypertrophy induced by treatment with 10 
μmol/L isoproterenol (Figure 1G), whereas it had no effect 
on the hypertrophy induced by phenylephrine (Figure 1L), 
indicating that PDE2 acts downstream of the β- rather than 
the α-adrenergic receptor. Consistently, Bay 60-7550 did not 
inhibit phenylephrine-induced NFAT nuclear translocation 
(Online Figure IG) and did not affect the nuclear translocation 
of NFAT in response to phenylephrine and selective inhibition 
of GSK3β (glycogen synthase kinase 3 beta) and JNK (c-Jun 
N-terminal kinases) (Online Figure IG), indicating that inhibi-
tion of PDE2 acts independently of this pathway.
Figure 2 . Phosphodiesterase 2 (PDE2) inhibition attenuates cardiac hypertrophy in vivo. A, Representative mid-ventricular magnetic 
resonance imaging (MRI) short-axis images of left ventricle in end diastole treated for 3 weeks as indicated. B, Left ventricular weight 
(LVW) calculated from MRI recordings divided by body weight (BW) as indicated. n=4 to 8 mice per group. C, Representative heart 
sections obtained from mouse hearts extracted 3 weeks after sham or transverse aorta constriction (TAC) operation in the absence or 
presence of treatment, as indicated. D, LVW/BW ratio plotted against the systolic pressure gradient calculated as a difference between 
right and left carotid systolic blood pressure (ΔP) at 3 weeks after sham operation, TAC, TAC+vehicle, or TAC+BAY 60-7550 (3 mg/
kg). E, Summary and comparison of mean LVW/BW ratio values calculated for all sham-operated, TAC-, TAC+vehicle–, or TAC+BAY 
60-7550–treated mice. F, Mean LVW/BW ratio values calculated for TAC-, TAC+vehicle–, or TAC+BAY 60-7550–treated mice presenting 
with a ΔP within the 30 to 40 mm Hg range. G, Representative images of picrosirius red staining of heart sections generated after 3 weeks 
of TAC and treatment with vehicle or BAY 60-7550. In each panel, the contour of a representative cell is highlighted with a black line. 
Scale bar =40 μm. H, Summary of myocyte cross-sectional area from sham-, TAC-, TAC+vehicle–, and TAC+BAY 60-7550–treated hearts 
(mean±SEM of at least n=213 cells per condition). One-way ANOVA and Tukey’s multiple comparison tests were performed in all the 
experiments. *P≤0.05; **P≤0.01; ***P≤0.005.
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To examine whether PDE2 inhibition also attenuates cardiac 
hypertrophy in vivo, adult C57Bl/6 mice were subjected to trans-
verse aorta constriction (TAC) for 3 weeks and concurrently treat-
ed with BAY 60-7550 (3 mg/kg) or with vehicle (Online Table 
I). The PDE2 inhibitor induced a significant reduction of cardiac 
hypertrophy as verified by echocardiography (Online Figure I-H 
and I-I), cardiac magnetic resonance imaging (Figure 2A and 
2B), and postmortem examination (Figure 2C–2H).
PDE2 overexpression results in cardiac myocyte hypertro-
phy both in vitro and in vivo. We next investigated the effect 
of increasing PDE2 activity in NRVMs by overexpressing a 
red fluorescent protein–tagged version of PDE2 (PDE2Awt-
mRFP). We found a significant increase in cell surface area 
(Figure 3A and 3B) and in nuclear translocation of NFAT-
GFP (Figure 3C) in transfected versus untransfected cells. 
Overexpression of a catalytically inactive version of the en-
zyme (dnPDE2Awt-mRFP) had no effect (Figure 3D and 5E). 
Similar results were found in ARVMs (Online Figure IIIA). 
To test whether overexpression of PDE2 results in hypertro-
phic growth in vivo, a recombinant adenoviral vector (Ad) 
expressing the PDE2A enzyme tagged with mCherry (AdV5/
PDE2Awt-mCherry) was injected in the heart of adult rats. 
Seven days after injection, the cell surface areas of transduced 
and untransduced myocytes dissociated from the same heart 
were compared. As shown in Figure 3E and 3F, PDE2Awt-
mCherry-expressing cardiomyocytes show a significant in-
crease in cell surface area as compared with untransduced 
cells; cardiomyocytes overexpressing the catalytically inac-
tive PDE2Adn-mCherry did not differ from untransduced 
cells (Figure 3E and 3G).
Antihypertrophic Effect of PDE2 Inhibition Is 
PKA-Dependent
PDE2 can degrade both cAMP and cyclic GMP26; there-
fore, its inhibition may result in an increase of both second 
messengers. To establish whether PKA or protein kinase G 
mediates the antihypertrophic effect of PDE2 inhibition, we 
measured cell surface area and NFAT-GFP nuclear translo-
cation in norepinephrine-treated NRVMs in the presence of 
selective kinase inhibitors. The selective protein kinase G in-
hibitor DT-227 did not affect the ability of BAY 60-7550 to 
significantly reduce hypertrophy (Figure 4A and 4B). As a 
control, we measured the effect of DT-2 on the antihypertro-
phic effect of selective inhibition of the cyclic GMP–specific 
PDE5 with sildenafil (10 nmol/L), previously reported to 
counteract hypertrophy via protein kinase G activity.28 We 
found that sildenafil alone had no effect on either cell sur-
face area or NFAT-GFP nuclear translocation (Online Figure 
IV), but DT-2 completely blocked the cyclic GMP–mediated 
Figure 3. Phosphodiesterase 2 (PDE2) overexpression induces cardiac myocyte hypertrophic growth in vitro and in vivo. A, 
Overlay of differential interference contrast (DIC) and fluorescence images showing in the same field one neonatal rat ventricular 
myocytes (NRVM) overexpressing Red fluorescent protein–tagged version of PDE2 (PDE2Awt-mRFP) and one untransfected control 
cardiomyocyte. Cell contour is highlighted in white (Scale bar: 10 μm). B, Cell surface area (3 independent experiments, n≥49) calculated 
for untransfected NRVMs or NRVMs overexpressing PDE2Awt-mRFP (pixel size =0.1075 μm). C and D, Percentage of cells showing 
nuclear translocation of nuclear factor of activated T cells (NFAT)-GFP measured for untransfected control NRVMs and NRVMs 
overexpressing PDE2Awt-mRFP or PDE2A2dn-mRFP (dominant negative phosphodiesterase 2-monomeric red fluorescent protein; 4 
independent experiments, total cell number ≥47). E, Representative images of untransduced (left) and transduced ARVMs expressing 
adenoviral vector (Ad) expressing the PDE2A enzyme tagged with mCherry (AdV5/PDE2Awt-mCherry; middle) or the catalytically inactive 
ADV5/PDE2Adn-mCherry (adeno virus 5-dominant negative phosphodiesterase 2-monomeric cherry; right). F, Summary of cell surface 
area of ARVMs transduced with AdV5/PDE2wt-mCherry and untransduced myocytes isolated from the same heart. G, Cell surface 
area of ARVMs obtained from hearts injected with AdV5/PDE2Adn-mCherry and expressing or not expressing the catalytically inactive 
recombinant enzyme. Consistent results were obtained from hearts from 3 different animals injected with AdV5/PDE2Awt-mcherry and 3 
animals injected with AdV5/PDE2Adn-mcherry; number of cells for each condition was ≥100. Pixel size =0.1613 μm. All data represent 
mean±SEM. For all experiments, t test statistical analysis was performed. *P≤0.05, ***P≤0.005.
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effect of sildenafil on norepinephrine-induced cell size in-
crease (Figure 4A) and NFAT-GFP nuclear translocation 
(Figure 4B). In contrast, selective PKA inhibition with my-
ristoylated protein kinase A inhibitor peptide (myrPKI)29 
completely abolished the antihypertrophic effects of BAY 
60-7550 (Figure 4C and 4D) without affecting the antihyper-
trophic effect of sildenafil (Figure 4C and 4D). In keeping 
with these findings, the effect of PDE2 knockdown on nor-
epinephrine-induced hypertrophy was completely blocked by 
myrPKI but was unaffected by DT-2 treatment (Figure 4E and 
4F). Consistent with a role for PKA activation downstream 
of PDE2 inhibition, we found that Bay 60-7550 significantly 
increases PKA-mediated phosphorylation of the fluorescence 
resonance energy transfer reporter AKAR4 (A kinase activity 
reporter 4) (Online Figure V). The role of PKA is further sup-
ported by the finding that the antihypertrophic effect of BAY 
60-7550 is completely blocked by the PKA inhibitors H89 and 
cAMPS-Rp (Figure 4G). In addition, we found that disrupting 
PKA–AKAPs interactions with the competing peptide Ht3130 
abolishes the effect of BAY 60-7550 on nuclear translocation 
of NFAT (Figure 4H), confirming a PKA-dependent mecha-
nism and indicating that a localized subset of PKA is involved. 
Thus, the antihypertrophic effect of PDE2 is PKA-mediated 
and protein kinase G–independent.
PDE2 Modulates a Local Pool of cAMP With 
Antihypertrophic Effects
PDE2 has been shown to be targeted to specific subcellular 
sites in NRVMs,18 a finding that we confirm here in ARVMs 
(Online Figure VI). A possible explanation for the oppo-
site effect on cell size observed on selective PDE inhibi-
tion is that blocking the activity of a localized PDE2 raises 
cAMP content in a specific subcellular microdomain that 
is linked to antihypertrophic effects, whereas inhibition of 
PDE3 and PDE4 increases cAMP at sites where prohyper-
trophic effectors are activated. If so, it should be possible 
to recapitulate the effect of selective pharmacological inhi-
bition by displacing the individual PDEs from their anchor 
Figure 4. The antihypertrophic effect of phosphodiesterases 2 (PDE2) inhibition is protein kinase A (PKA)–dependent. Cell surface 
area (3 independent experiments, n≥72; A) and nuclear factor of activated T cells (NFAT)-GFP nuclear translocation (3 independent 
experiments, n ≥50; B) measurements for untreated control, neonatal rat ventricular myocytes (NRVMs) treated for 48 hours with 
norepinephrine (NE; 10 μmol/L) or DT-2 (10 μmol/L) or treated with DT-2 in combination with NE, NE and BAY 60-7550 (10 μmol/L), or 
NE and sildenafil (10 nmol/L) as indicated. Cell surface area (3 independent experiments, n≥54; C) and percentage of NFAT-GFP nuclear 
translocation (4 independent experiments, n ≥76; D) calculated for untreated control, NRVMs treated for 48 hours with NE (10 μmol/L) 
or myristoylated protein kinase A inhibitor peptide (myrPKI) alone (10 μmol/L), or treated in combination with NE, NE and BAY 60-7550 
(10 μmol/L), or NE and sildenafil (10 nmol/L) as indicated. E and F, NFAT-GFP nuclear translocation measurements (3 independent 
experiments) for untreated control, NE (10 μmol/L)-treated NRVMs, or NRVMs treated with NE (10 μmol/L) and transfected either with 
siPDE2 or with the control oligo siGLO Red in the presence or absence of DT-2 (10 μmol/L) or of myrPKI (10 μmol/L). G, [3H] leucine 
incorporation assay performed in NRVMs treated with NE in combination with BAY 60-7550 (10 μmol/L) and the PKA inhibitors H89 or 
cAMPS-Rp (n≥4 independent experiments). H, NFAT-GFP nuclear translocation measurements (2 independent experiments) for untreated 
control and NRVMs transfected with Ht31 and treated with NE and BAY 60-7550. All data represent mean±SEM. One-way ANOVA and 
Tukey’s multiple comparison tests were used. Pixel size =0.1075 μm. *P≤0.05, **P≤0.01, ***P≤0.005.
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sites within the cell, a maneuver that has been previously 
used to generate a localized increase in cAMP.16,31 To test 
this, we measured cell surface area in NRVMs overex-
pressing fluorescent protein–tagged chimeras of catalyti-
cally inactive mutants of PDE2A (PDE2Adn),16 PDE3A2 
(PDE3A2dn), and PDE4D3 (PDE4D3dn).32 We found 
that displacement of endogenous PDE4D3 (Figure 5A) or 
PDE3A2 (Figure 5C) resulted in hypertrophy and did not 
further increase the hypertrophy induced by norepineph-
rine treatment (Figure 5B and 5D), reproducing the effects 
of pharmacological inhibition. In contrast, displacement of 
endogenous PDE2A did not affect cell size in untreated 
myocytes (Figure 5E), but significantly reduced the hy-
pertrophy induced by norepinephrine (Figure 5F). Similar 
results were found for nuclear translocation of NFAT-GFP 
(Online Figure VIIA and VIIB) and in ARVMs (Online 
Figure VIIC–VIIF). These data support a model whereby 
different PDEs localized to different intracellular locations 
control distinct pools of cAMP with opposite effects on 
cardiac myocyte cell size.
Antihypertrophic Effect of PDE2 Inhibition Is 
Mediated by PKAII
The data presented to date demonstrate that a local pool of 
cAMP with antihypertrophic effects is selectively regulated 
by PDE2-mediated hydrolysis. To gain some insight into 
the subcellular localization of such a pool, we measured 
the cAMP signal generated on selective PDE2 inhibition 
using RI_epac and RII_epac, 2 fluorescence resonance en-
ergy transfer–based reporters for cAMP that localize to the 
sites where PKAI and PKAII, respectively, normally reside 
within the cell. These reporters target to different AKAPs 
and selectively detect cAMP signals within distinct sub-
cellular compartments.6 PDE2 inhibition potentiates the 
cAMP response to 10 nmol/L norepinephrine (Figure 6A) 
Figure 5 . Phosphodiesterases 2 (PDE2) modulates a local pool of cAMP with antihypertrophic effects. Neonatal rat ventricular 
myocytes (NRVM) were transfected with catalytically inactive PDE4D3 (A and B), catalytically inactive PDE3A2 (C and D), or catalytically 
inactive PDE2A (E and F), and cell surface area was measured in the absence or presence of 10 μmol/L norepinephrine (NE) for 48 hours. 
In each panel, the cell surface area is shown as mean±SEM on the left, and on the right, an overlay of differential interference contrast 
(DIC) and fluorescence images showing one NRVM overexpressing the catalytically inactive PDE and in the same field a nontransfected 
control cardiomyocyte is presented. For all conditions, n≥25 cells from 3 independent experiments. Pixel size =0.1075 μm. Scale bar: 10 
μm. For all experiments, t test statistical analysis was performed. ***P≤0.005; ns=not significant.
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or 10 nmol/L isoproterenol (Online Figure VIIIA), both 
in the PKAI and PKAII compartments, whereas PDE3 
inhibition affects the cAMP response exclusively in the 
PKAI compartment (Figure 6B and Online Figure VIII B). 
Similar results were found in ARVM (Online Figure VIIID 
and VIIIE). As inhibition of PDE3 promotes, rather than 
inhibits, hypertrophy (Figure 1A and 1D), we hypothesized 
that the cAMP pool under the control of PDE2 and respon-
sible for the antihypertrophic effect is associated with the 
PKAII compartment. Consistent with this model, we found 
that, on inhibition of PDE2, PKA-mediated phosphoryla-
tion is significantly higher in the PKAII compartment as 
opposed to the PKAI compartment (Figure 6D). In addi-
tion, the effect of PDE2 inhibition on hypertrophy was 
completely blocked by super A kinase Anchoring protein-
in silico (SuperAKAP-IS),12 a peptide that disrupts selec-
tively the interaction between PKAII and AKAPs, whereas 
the PKAI–AKAP selective disruptor regulatory I anchoring 
disruptor (RIAD)33 had no effect (Figure 6E and 6F), con-
firming that a subset of AKAP-anchored PKAII mediates 
the antihypertrophic effect downstream of PDE2 inhibi-
tion. Interestingly, the prohypertrophic effects of PDE3 and 
PDE4 inhibition, although PKA-dependent (Figure 6G), 
were not affected by treatment with either SuperAKAP-IS 
or RIAD (Figure 6H and 6I), suggesting that the prohy-
pertrophic effect of PDE3 and PDE4 inhibition does not 
require an AKAP-anchored subset of PKA.
Antihypertrophic Effect of PDE2 Inhibition 
Requires PKA-Mediated Phosphorylation of NFAT
Nuclear translocation of NFAT regulates pathological cardiac 
hypertrophy.34 PKA phosphorylates NFAT at Ser 245, Ser 
269, and Ser 294,35 thus preventing its nuclear translocation.36 
We therefore hypothesized that the antihypertrophic effects of 
PDE2 inhibition may rely on PKA-mediated phosphorylation 
of NFAT. Consistent with our hypothesis, treatment of NRVM 
with Bay 60-7550 results in strong enhancement of PKA-
dependent phosphorylation of NFAT both in nonhypertrophic 
(Figure 7A) and norepinephrine-hypertrophyed (Figure 7B) 
cells. In addition, in a pull-down of PKA-phosphorylated 
proteins from lysates of NRVMs hypertrophied in vitro, the 
amount of PKA-phosphorylated NFAT-GFP was significantly 
higher in BAY 60-7550–treated than in control cells (Online 
Figure IXC and IXD). Similar results were obtained from 
NFAT-GFP pull-downs probed with a PKA substrate antibody 
(Online Figure IXA and IXB). Notably, increased phosphory-
lation on inhibition of PDE2 was confirmed when probing for 
endogenous NFAT (Figure 7C). It is interesting to note that 
PDE4 inhibition increases PKA-mediated phosphorylation 
of overexpressed NFAT-GFP (Figure 7B and Online Figure 
IXC and IXD), in line with the large global rise in cAMP 
that it generates (Figure 1C). Overexpressed NFAT is likely 
to distribute to sites where endogenous NFAT normally is not 
present, and therefore, it is expected to become phosphory-
lated on PDE4 inhibition. However, PDE4 inhibition does not 
Figure 6 . Protein kinase A type II (PKAII) mediates the antihypertrophic effects of BAY 60-7550. Quantification of cAMP changes 
induced by BAY 60-7550 (10 μmol/L), norepinephrine (NE; 10 nmol/L), NE plus BAY 60-7550 (A), or by cilostamide (10 μmol/L), NE 
(10 nmol/L), or NE plus cilostamide (B), or by rolipram (10 μmol/L), NE (10 nmol/L), or NE plus rolipram (C) in neonatal rat ventricular 
myocytes (NRVMs) expressing either RI-epac or RII-epac. n≥4. D, Quantification of PKA isoform-selective activation induced by 
isoproterenol (10 nmol/L) and BAY 60-7550 measured in NRVMs expressing the FRET sensors RI_AKAR3 or RII_AKAR3 (regulatory 
I_A kinase activity reporter 3 or regulatory II_A kinase activity reporter 3).16 n≥3. E, Percentage of cells showing nuclear translocation 
of nuclear factor of activated T cells (NFAT)-GFP (F) and cell size measured for NE-treated or NE+BAY 60-7550–treated NRVMs 
untransfected or transfected with either SuperAKAP-IS or RI-AD. n≥4. G, Cell surface area measurements of NRVMs treated for 48 
hours as indicated. Cell size measured for untransfected NRVMs or NRVMs transfected with either super A kinase Anchoring protein-in 
silico (SuperAKAP-IS) or RI-AD and treated with cilostamide (H) or rolipram (I) as indicated; n≥34. All data represent mean±SEM. For 
experiments in A–D, a t test statistical analysis was performed. In E–I, 1-way ANOVA and Tukey’s multiple comparison tests were used. 
***P≤0.005; **P≤0.01; *P≤0.05; ns=not significant.
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significantly affect the phosphorylation of endogenous NFAT 
(Figure 7C), further confirming that PDE2 and PDE4 act on 
distinct pools of cAMP and have distinct effects on the en-
dogenous protein.
To further test whether the antihypertrophic effect of BAY 
65-7550 is mediated by PKA-dependent phosphorylation of 
NFAT, we generated a PKA phosphorylation-resistant form 
of NFAT-GFP by introducing serine-to-alanine substitutions 
at positions 245, 269, and 294. BAY 60-7550 reduced the 
translocation of wild-type NFAT-GFP, but did not affect nu-
clear translocation of triple-mutant NFAT-GFP (Figure 7D), 
indicating that the PKA phosphorylation sites on NFAT are 
Figure 7 . The antihypertrophic effect of phosphodiesterases 2 (PDE2) inhibition requires protein kinase A (PKA)–mediated 
phosphorylation of nuclear factor of activated T cells (NFAT). A, Representative GFP-pull down experiment from lysate of neonatal rat 
ventricular myocytes (NRVMs) expressing NFAT-GFP, PKI-mCherry, or mCherry. Cells were treated for 10 minutes with norepinephrine (NE; 
10 μmol/L) and BAY 60-7550 (10 μmol/L) as indicated. Blots were probed with anti-phospho-PKA substrate, anti-GFP, and anti-GAPDH 
antibodies. n=3. B, Representative GFP-pull down experiment from lysate of NRVMs expressing NFAT-GFP and treated for 48 hours with 
NE (10 μmol/L), BAY 60-7550 (10 μmol/L), and rolipram (10 μmol/L) as indicated. Blots were probed with anti-phospho-PKA substrate, 
anti-GFP, and anti-GAPDH antibodies. n=3.C, Representative immunoprecipitation of endogenous NFAT performed on lysates from NRVMs 
treated for 48 hours with NE, BAY 60-7550, and rolipram as indicated. Blots were probed with anti-phospho-PKA substrate, anti-NFAT, 
and anti-GAPDH antibodies. n=3. D, Nuclear translocation of NFAT-GFP wild-type or NFAT-GFP triple mutant (S245A/S269A/S294A) 
calculated for untreated NRVMs, NRVMs treated for 48 hours with NE (10 μmol/L), NE and BAY 60-7550 (10 μmol/L), NE and sildenafil 
(10 nmol/L), or NE and rolipram (10 μmol/L); n=3 independent experiments. E, Representative immunoprecipitation of endogenous NFAT 
performed on mouse left ventricles whole cell lysates from sham, transverse aorta constriction (TAC)+vehicle, or TAC+BAY 60-7550 mice as 
indicated. Blots were probed with anti-phospho-PKA substrate, anti-NFAT, and anti-GAPDH antibodies. Representative of 4 independent 
experiments, F, B natriuretic peptide (BNP; left) and regulator of calcineurin 1 (RCAN1.4; right) mRNA levels measured in left ventricular 
(LV) samples from sham, TAC+vehicle, or TAC+BAY 60-7550 mice as indicated (n=3–7). G, Quantification of NFAT luciferase activity in 
LV homogenates from NFAT luciferase reporter mice subjected to TAC and 2 weeks treatment with BAY 60-7550 or vehicle, normalized 
to sham values. Four repeats per sample were performed. All data represent mean±SEM. In D, t test was utilized. One-way ANOVA and 
Tukey’s multiple comparison tests were performed in F and G. Pixel size =0.1075 μm. *P≤0.05; **P≤0.01; ns=not significant.
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required for BAY 60-7550 to prevent norepinephrine-induced 
nuclear translocation of NFAT. In contrast, treatment of hyper-
trophic myocytes with sildenafil significantly blocked nuclear 
translocation of both wild-type and triple-mutant NFAT-GFP 
(Figure 7D), as expected given that the antihypertrophic effect 
mediated by sildenafil is independent of PKA phosphorylation 
(Figure 2 and Nickl et al27). Inhibition of PDE4 with rolipram 
did not affect the nuclear translocation of either wild-type or 
triple-mutant NFAT (Figure 7D). In further support of the role 
of a local pool of cAMP in the antihypertrophic effect of PDE2 
inhibition, overexpression of PDE2Adn-mRFP in norepineph-
rine-treated NRVMs reduced nuclear translocation of NFAT-
GFP (Online Figure XA) but not of triple-mutant NFAT-GFP 
(Online Figure XB). In addition, in the presence of triple-mu-
tant NFAT-GFP, PDE2Adn-mRFP was unable to counteract 
norepinephrine-induced hypertrophy (Online Figure XC and 
XD), further confirming that the antihypertrophic effect of 
PDE2 requires PKA-mediated phosphorylation of NFAT. The 
involvement of NFAT phosphorylation and NFAT-dependent 
gene transcription in the antihypertrophic effect of PDE2 in-
hibition in vivo was confirmed in experiments where we mea-
sured NFAT phosphorylation (Figure 7E) and mRNA levels 
for BNP (B natriuretic peptide) and RCAN1 (regulator of cal-
cineurin 1) (Figure 7F), 2 genes that are transcribed under the 
control of NFAT34,37 in sham-operated, TAC+vehicle–treated, 
and TAC+BAY 60-7550–treated mice. We found that treat-
ment with the PDE2 inhibitor significantly enhances NFAT 
phosphorylation and reduces the level of expression of NFAT-
dependent genes, thus reversing the molecular fingerprint of 
pathological hypertrophy. To further support our conclusion 
that PDE2 inhibition counteracts cardiac hypertrophy in vivo 
via an NFAT-dependent mechanism, we subjected NFAT re-
porter mice38 to TAC and randomization to treatment with 
BAY 60-7550 or vehicle for 2 weeks (Online Table II and 
Online Figure XI). In line with our previous results, BAY 
60-7550–treated NFAT reporter mice showed reduced cardiac 
hypertrophy (Online Figure XI) and corresponding NFAT 
luciferase activity (Figure 7G) after TAC as compared with 
vehicle-treated mice.
Discussion
In this study, we identify PDE2 as a regulator of cardiac 
hypertrophy by providing strong evidence, in vitro and in 
vivo, that overexpression of PDE2 is sufficient per se to 
induce hypertrophy and that inhibition of PDE2 counter-
acts cardiac myocyte hypertrophic growth, an effect that 
relies on cAMP-dependent activation of PKA. Our data re-
veal a completely novel mechanism through which cAMP 
signaling impacts cardiac myocyte cell size that strictly de-
pends on the subcellular site at which the cAMP signal is 
generated. Thus, inhibition of PDE2 generates a local pool 
of cAMP with antihypertrophic effects, whereas the rise 
in cAMP generated via inhibition of PDE3 or PDE4 has 
prohypertrophic effects. We demonstrate here for the first 
time that spatially distinct pools of cAMP can be generated 
downstream of βAR (beta adrenergic receptor) activation 
with opposing effects on myocyte size.
Using targeted fluorescence resonance energy transfer 
reporters for cAMP and selective displacement of PKAI 
and PKAII from their anchoring sites on AKAPs, we unveil 
a complex involvement of cAMP and PKA in the regula-
tion of cardiac myocyte hypertrophy. Inhibition of PDE2 
and of PDE4 increases cAMP in both the PKAI and PKAII 
compartments, yet the effect on cell size is opposite. To ra-
tionalize these findings, it should be noted that there are mul-
tiple PKAI–AKAP and PKAII–AKAP complexes in cardiac 
myocytes7 and that the PKAI- and PKAII-targeted fluores-
cence resonance energy transfer reporters do not discrimi-
nate between individual complexes. Our findings support 
a model whereby a pool of cAMP generated in the PKAII 
compartment on PDE2 inhibition counteracts hypertrophy, 
whereas a pool of cAMP generated on inhibition of PDE4 
within the PKAII compartment, but presumably involving 
different PKAII–AKAP complexes, has no effect on cell size. 
Alternatively, inhibition of PDE4 may affect the same pool of 
cAMP under the control of PDE2, but a concomitant increase 
in cAMP at a different site has a dominant, prohypertrophic 
effect. In support of the latter, using PKA–AKAP-selective 
disruptors, we find that inhibition of PDE4, as well as inhibi-
tion of PDE3, results in hypertrophy via activation of a subset 
of PKA that is not anchored to AKAPs.
It is well established that adrenergic stimulation can ini-
tiate cardiac hypertrophy via generation of cAMP and acti-
vation of PKA,39,40 as confirmed by PKA knockout studies in 
which deletion of PKA subunits is protective against hyper-
trophy.41 Other studies, however, have suggested that com-
ponents of the β-adrenergic signaling pathway may play a 
protective role in response to hemodynamic overload. For 
example, it has been reported that overexpression of some 
types of adenylyl cyclase improve cardiac function23 and 
that PKA-mediated phosphorylation of histone deacetylase 
5 prevents its nuclear export and results in decreased car-
diac myocyte size.42 The present data support the coexis-
tence within the same cell of multiple spatially segregated 
cAMP/PKA signaling pathways that can alternatively pre-
vail depending on the status of the cell and provide a pos-
sible mechanistic basis for the dichotomy reported in the 
literature on the role of PKA on the development of cardiac 
pathology.
Dephosphorylation of NFAT and its subsequent translo-
cation to the nucleus is regulated by the Ca2+-calmodulin–
dependent phosphatase, one of the most potent activators 
of the hypertrophic program.34 Ca2+-calmodulin–dependent 
phosphatase can directly interact with several AKAPs, in-
cluding AKAP1,43 AKAP5,44 and AKAP6,45 all of which bind 
PKA type II. In addition, studies suggest that regulation of 
Ca2+-calmodulin–dependent phosphatase activity occurs via 
a specific microdomain of Ca2+,46 further supporting a local 
regulation of this phosphatase. Although NFAT has not been 
reported to be part of a macromolecular complex organized 
by AKAPs, there is some evidence that this transcription 
factor also resides in distinct cytosolic domains and that 
its regulation occurs locally.47 Based on the above observa-
tions, a possible scenario is therefore that PDE2 controls a 
pool of cAMP that activates an AKAP-bound PKA type II 
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to phosphorylate a local NFAT, possibly counterbalancing 
its dephosphorylation by a local Ca2+-calmodulin–dependent 
phosphatase. Further studies are required to explore this 
hypothesis.
Recently, it has been reported by Mehel et al48 that nor-
epinephrine treatment does not significantly increase cell 
size in ARVM-overexpressing PDE2. Based on this obser-
vation, the authors suggest that PDE2 may be protective 
against pathological hypertrophy. Unfortunately, that report 
showed only normalized values of the effect of norepineph-
rine on cells overexpressing PDE2 and not the effect on cell 
size of overexpression of PDE2 per se, making the data dif-
ficult to interpret. We note, however, that although the au-
thors draw the opposite conclusion, the data as reported by 
Mehel et al are compatible with the findings described in 
the present report. If we were to express the effect of nor-
epinephrine on cell size relative to control cells and relative 
to PDE2 overexpressing cells, as reported in the Mehel et al 
study, the latter group would show a significantly blunted 
effect of norepinephrine treatment (see Online Figure XII 
and refer to Online Figures IIIA, IIIB, VIIE, and VIIF). 
However, this way of presenting the data is misleading be-
cause overexpression of PDE2 already results in significant 
hypertrophy compared with control cells and, thus, reduc-
es the relative effect of norepinephrine (see Figure 3 and 
Online Figure III).
Our findings may have important clinical implications. 
The in vivo data indicate that inhibition of PDE2 counteracts 
hypertrophy in a TAC model. Additional investigations will 
be required to establish whether this would protect against 
progression toward heart failure and to determine the rel-
evance of PDE2 activity to human cardiac hypertrophy. 
Increased PDE2 expression has been reported in early rat 
cardiac hypertrophy,49 as well as in failing human hearts,50 
suggesting that increased activity of this enzyme may be 
involved in the pathogenesis of the disease. It has been sug-
gested that the hypertrophic response to pathological stress 
is never truly adaptive51 and that inhibition of hypertrophy 
is beneficial.52–54 In addition, the possibility to control the 
local concentration of cAMP at specific sites via selective 
inhibition of PDEs has been previously recognized as a 
possible approach to improving clinical outcomes,55 and a 
phase 3 trial has been recently concluded where the PDE3-
selective inhibitor enoximone was used in combination with 
β-blockade to couple inhibition of adverse β-adrenergic 
signaling with restoration of phospholamban phosphoryla-
tion.56 From this perspective, PDE2 may represent a particu-
larly interesting target. In vitro studies have demonstrated 
that the pool of cAMP generated on inhibition of PDE2 
mediates positive inotropic effects,18,57 and the ability to 
manipulate a pool of cAMP that simultaneously exerts posi-
tive inotropy and counteracts cardiac myocyte hypertrophic 
growth may represent a significant improvement over exist-
ing therapeutic strategies.
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What Is Known?
•	 3′-5′-Cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) 
signals are critical regulators of heart function in health and disease.
•	 Phosphodiesterases (PDEs), the enzymes that degrade cAMP, modu-
late the local activity of cAMP/PKA, resulting in compartmentalized 
signaling.
•	 Different PDE isoenzymes regulate spatially distinct pools of cAMP, but 
the role of these individual local cAMP pools in the pathogenesis of 
heart disease is unclear.
What New Information Does This Article Contribute?
•	 Distinct pools of cAMP affect cardiac myocyte hypertrophic growth 
differently.
•	 Inhibition of PDE3 and PDE4 results in cardiac hypertrophy, whereas 
inhibition of PDE2 is antihypertrophic.
•	 The antihypertrophic effect of PDE2 inhibition relies on a local increase 
in cAMP and PKA-mediated phosphorylation of the nuclear factor of 
activated T cells.
cAMP/PKA signaling controls cardiac function, and its downregu-
lation is involved in the pathophysiology of cardiac hypertrophy, 
an early feature of cardiac remodeling leading to heart failure. 
Therapeutic intervention aimed at sustaining contractility by rais-
ing cAMP levels, although effective in the short term, is associat-
ed with increased mortality in the long term. The rationale of our 
study was based on the hypothesis that different pools of cAMP 
may have either positive or negative effects on cardiac function 
and that available treatments targeting the cAMP pathway fail 
to selectively affect those pools of cAMP involved in sustaining 
contractility and have a predominant negative effect by promot-
ing cardiac remodeling. Here we investigate the effects of selec-
tively inhibiting individual PDE isoforms on cardiac hypertrophy. 
We find that although inhibition of PDE3 or PDE4 is prohyper-
trophic, inhibition of PDE2 mediates antihypertrophic effects. We 
demonstrate that the antihypertrophic effect of PDE2 inhibition 
involves the generation of a local pool of cAMP and activation of 
a subset of PKA type II that phosphorylates the prohypertrophic 
transcription factor nuclear factor of activated T cells, blocking its 
nuclear translocation. Our findings demonstrate, for the first time, 
the involvement of PDE2 in the development of cardiac hypertro-
phy and identify PDE2 as a potential novel therapeutic target to 
treat this condition.
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Supplemental Material  
Materials and Methods 
Reagents. Norepinephrine, cilostamide, rolipram, and forskolin were from Sigma‐Aldrich. 
BAY 60‐7550 was from Alexis. Collagenase A was from Roche, Pancreatin from Sigma, 
Laminin (mouse) from BD Biosciences. Phosphate‐Buffered Saline (PBS), DMEM High 
Glucose, MEM199, Horse Serum, New born Calf Serum, Penicilline/Streptomycine (10,000 
units of penicillin (base) and 10,000 μg of streptomycin (base)/mL) and Glutamine were from 
Invitrogen. Sildenafil was a kind gift from Sharron Francis, Vanderbilt University School of 
Medicine, Nashville, Tennessee. DT-2 was from BioLog and myrPKI from Calbiochem. BIO 
was purchased from EMD Biosciences and SP6000125 was from Calbiochem. Antibody 
against GFP was purchased from Abcam and was used according to the manufacturer’s 
instructions. Anti-phospho-RXXS/T antibody was from Cell Signaling. 
 
Mouse models. All animal procedures in this study were carried out according to the Home 
Office regulations regarding experiments with animals in the UK, the European Community 
guiding principles for the care and the ‘Regulations on Animal Experimentation’ under The 
Norwegian Animal Welfare Act and approved by the Norwegian Animal Research Authority 
(FDU application 7105) and use of animals and the projects were approved by the local ethic 
committees. Male C57Bl/6 mice were from Charles River. Pressure overload was produced 
by TAC as described in1. Briefly, thoracotomy was performed in the second intercostal 
space, the transverse aorta between right and left carotid arteries was isolated and a 7-0 
nylon suture ligature was placed around the aorta, with the two ends of the suture left 
outside the chest. Hemodynamic recording was continuously acquired under basal 
conditions and during a 5 s acute transverse aortic occlusion produced by gently pulling on 
the suture ends. The suture ligature was tied against a 27 G needle, which was rapidly 
removed to result in a significant pressure load on the LV. The chest was closed and mice 
were allowed to recover. Sham- operated mice underwent the same operation, but without 
aortic constriction. Treatment with PDE2 inhibitor (BAY 60-7550, 3 mg/kg) or vehicle 
(sunflower oil) was provided by intraperitoneal injection, three times a day.  
In a subset of the TAC mice echocardiography was performed 24h after the TAC-procedure 
with a Vevo2100 system (FUJIFILM VisualSonics Inc, Toronto, Canada) to obtain the 
maximal flow velocity over the TAC. Stratification was performed by assessing the flow 
velocity over the TAC, before randomization to either treatment with PDE2 inhibitor (BAY 60-
7550, 3 mg/kg x 3 per day with intraperitoneal injection for 21 days) or corresponding vehicle 
(sunflower oil).  
In a separate set of experiments, cardiac specific NFAT-reporter mice 2 (kindly donated by 
Professor Jeffrey Molkentin, Department of Pediatrics, Cincinnati Children's Hospital Medical 
Center, University of Cincinnati, US) with nine copies of an NFAT-binding site from the 
interleukin-4 promoter inserted upstream of the luciferase gene underwent the same 
procedure and were treated with PDE2 inhibitor over 14 days to measure the role of PDE2 
inhibition on NFAT-activity in hypertrophic hearts. 
3 weeks after surgical procedure, pressure was measured under anaesthesia as systolic 
pressure gradient between left and right carotid arteries using a high-fidelity 
micromanometer catheter (Millar Instruments). Immediately following, the mice were 
weighed then the hearts were excised and the ratio of left ventricular weight to body weight 
(LVW/BW) was calculated. 
 
 
Echocardiography, magnetic resonance imaging and cardiac phenotyping. Left 
ventricular mass was estimated with cardiac MRI (CMRI), echocardiography and measured 
post mortem at the end of the protocol. CMRI was performed on a 9.4T preclinical MR 
system (Agilent Technologies, Inc., CA) with high-performance gradient (60 mm ID, rise time 
180 μs, max strength 100 gauss/cm) and a quadrature volume RF coils (35 mm ID, Rapid 
2 
 
Biomedical, Washington, USA) as previously described 3. Mice were sedated and mask 
ventilated with a mixture of O2 and 1.0-1.5% isoflurane during the protocol, and body 
temperature was maintained by heated air guided by continuous body temperature recording 
during the protocol. CMRI cine loops were acquired with ECG-triggering and respiration 
gating using a motion compensated gradient echo sequence. Apical to basal left ventricular 
short-axis slices (8-10) were acquired with echo-/repetition time=2.1/4.6 ms; field-of-view 
=25.6x25.6 mm; acquisition matrix 128x128; slice thickness =1.0 mm; flip angle 15°; 
averages =2. Mass estimates were obtained both in systole and diastole, and <5% variance 
was accepted.  
Left ventricular mass was calculated with the following formula from echocardiography: 
(IVSd + LVDd + PWDd)^3 – LVDd^3, where LVDd is the left ventricle diameter in diastole  
and IVSd/PWDd is the interventricular septum and posterior wall thickness in diastole, 
respectively. After final echocardiography, left ventricular (LV) mass was measured by 
cardiac excision in deep surgical anesthesia and rapid dissection of the LV chamber, which 
was weighed and frozen in liquid nitrogen for further analysis.  
 
 
Histology. Paraffin-embedded left ventricles were cut into 5 µm slices. Sections were 
stained with Picrosirius red (Fluka, Buchs, Switzerland) as described1. Cross-sectional areas 
were measured using the ImageJ software (National Institutes of Health). Appropriate cross-
sections were defined as those showing nearly circular capillary profiles and nuclei. 
 
NRVMs culture, treatment and transfection. Primary cultured cardiac ventricular myocytes 
were isolated from 1 to 2-days old Sprague-Dawley rats (Charles River Laboratories 
Wilmington, MA) as previously described4. Cells were cultured in 1st day medium  (DMEM 
High Glucose, MEM199, Horse serum, New born Calf serum, Glutamine, Pen/Strep) for 24 
hours before switching to a serum-free medium containing DMEM High Glucose, MEM199, 
Insulin-Transferring-Selenium-X Supplement, Glutamine, Pen/Strep. After 24 hours cells 
were treated for 48 hours with norepinephrine (10 μmol/L) and/or other stimuli, as indicated. 
NRVMs were transfected with Transfectin Lipid Reagent (BioRAD), following the supplier’s 
instructions. NFATC1-GFP was a kind gift from Stefano Schiaffino, University of Padova. 
NFATC1-GFP triple mutant was generated by introducing the S245A, S269A and S294A 
mutations by site directed mutagenesis using standard molecular biology techniques.  
ARVMs culture, treatment and adenoviral delivery. Wistar rats aged 16 weeks were 
sacrificed by cervical dislocation. Single cardiomyocytes were isolated as previously 
described5. Briefly, hearts were rapidly removed, cannulated, perfused and digested with 0.6 
mg mL-1 collagenase type I (Worthington) and 0.04 mg mL-1 protease type XIV (Sigma). 
Isolated cardiomyocytes were resuspended in MEM199 medium supplemented with 5 
mmol/L creatine (Sigma), 5 mmol/L taurine (Sigma), 2 mmol/L carnitine (Sigma), 1% 
Pen/Strep and plated on laminin-coated 24 mm coverslips. After 2 hours undigested tissue 
and unattached cells were washed off and the remaining cardiomyocytes were treated with 
different stimuli and/or transduced with AdV5/PDE2A wild type or AdV5/PDE2A D685A-
D796A (at 100 PFU/cell) for 24h. 
Adenoviral vector generation. PDE2A wild type and PDE2A D685A-D796A were cloned 
into the pShuttle-CMV vector and transferred by homologous recombination into the 
pAdEasy-1 vector and then transfected into 293 cells to generate AdV5/CMV/PDE2A wild 
type and AdV5/CMV/PDE2A D685A-D796A (using AdEasy™ XL Adenoviral Vector System 
from Agilent Technologies - Stratagene Products). For in vivo experiments AdV5-PDE2A 
wild type-mCherry and AdV5-PDE2A D685A-D796A-mCherry produced by Vector Biolabs 
were purified and titrated using standard techniques6.  
Intracardiac injection of AdV5-PDE2A mcherry. In vivo experiments were performed in 
20-24 week old Wistar Kyoto (WKY) male rats according to the Home Office regulations 
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regarding experiments with animals in the UK. Briefly, the animal underwent isofluorane 
anesthesia (2.5%) and endotracheal intubation. Under sterile conditions, left thoracotomy 
was performed in the fourth intercostal space, the left lung collapsed and the pericardium 
opened. Direct intramyocardial injection of the apical region of the exposed heart was carried 
out using 5 injections of 50 μL volume for a titre of 5x108 pfu recombinant adenovirus (AdV5-
PDE2A wild type mCherry or AdV5-PDE2A D685A-D796A-mCherry) in a total volume of 250 
μL in sterile PBS using a 29 G needle. Lungs were re-inflated and the chest was rapidly 
closed. The animal was given post-operative analgesia (buprenorphine (0.05 mg/kg) and 
carprofen (5 mg/kg) and closely monitored until full recovery from anaesthesia. 7 days after 
injection the rat was sacrificed by cervical dislocation, and single cardiac myocytes were 
isolated and cell surface area measured in both transduced (mCherry positive) and 
untransduced cells. 
Real-time PCR. Total RNA was extracted from cultured NRVMs using RNeasy® Mini Kit 
(Qiagen) and reverse transcription of RNA samples was carried out by using QuantiTect® 
Reverse Transcription Kit (Qiagen) according to manufacturer’s instructions. For PDE2, the 
TaqMan® Gene Expression Assay Rn00579346_m1 from Applied Biosystems was utilised. 
18S rRNA Primers and TaqMan probe sequences; Forward: 5’-
CGCGGTTCTATTTTGTTGGT-3’, Reverse: 5’-CGGTCCAAGAATTTCACCTC-3’, TaqMan: 
5’-FAM-TGAGGCCATGATTAAGAGGG-TAM-3’. Real-time PCR reactions were prepared 
using Platinum® Quantitative PCR SuperMix UDG with ROX (Invitrogen) and performed in a 
7300 Real time PCR System (Applied Biosystems). For quantification of BNP and RCAN1, 
frozen left ventricular samples were homogenised using the Precellys tissue 
homogeniser (2 times for 20 sec), total RNA was extracted using aRNeasy Fibrous 
Tissue Mini Kit (Qiagen) and reverse transcription of RNA samples was carried out by 
using QuantiTect® Reverse Transcription Kit (Qiagen) according to manufacturer’s 
instructions. The primer sequences used for GAPDH are the following; Forward: 
ATGACAACTTTGTCAAGCTCATTT, Reverse: GGTCCACCACCCTGTTGCT. For BNP; 
Forward: AAGGGAGAATACGGCATCATTG, Reverse: ACAGCACCTTCAGGAGATCCA. 
For RCAN1.4; Forward: CCCGTGAAAAAGCAGAATGC, Reverse: 
TCCTTGTCATATGTTCTGAAGAGGG. 
PDE2 knock down. Knock down of PDE2A was achieved using a siGENOME SMARTpool 
siRNA (125 nmol/L) (M-094898-00-0020, Rat PDE2A, NM_031079, Thermo scientific) as 
previously described5. Rescue of PDE2 was performed by co-transfection of a plasmid 
containing PDE2Awt-mRFP and a siRNA sequence designed to target the 3′-untranslated 
region (UTR) of PDE2 (5’-GCAGAAGGAATTCGAGATT-3’, Thermo Scientific), a region that 
is not present in the plasmid sequence. Control experiments were carried out using siGLO 
Red transfection indicator (125 nmol/L) according to manufacturer’s instructions (D-001630-
02-20, Thermo scientific). 
Cell size and NFAT-GFP nuclear translocation measurements. Images of single adult or 
neonatal rat ventricular myocytes were taken in brightfield mode on an Olympus IX71 
inverted microscope, Olympus PlanApoN objective, NA 1.42 oil, 0.17/FN 26.5, and Meta 
imaging series 7.1, MetaMorph, (Molecular Devices). When required, epifluorescence 
microscopy images were taken using either YFP illumination set (excitation filter ET500/30x, 
dichroic mirror T515LP, emission filter ET535/30m, Chroma Technology) or an RFP set 
(TxRed-A-Basic-000, single band excitation filter FF01-559/34-25, dichroic mirror FF585-
Di01-25x36, single band emitter FF01-630/69-25, Semrock) Cell surface area was 
calculated by drawing a region of interest (ROI) including the cell and by counting the 
number of pixels within the ROI. One pixel corresponds to 0.1075 μm when images are 
collected with 60x objective (experiments with NRVMs), or to 0.1613 μm when images are 
acquired with 40x objective (ARVMs experiments). For NFAT-GFP experiments, cells scored 
as positive for NFAT-GFP nuclear translocation were those showing a GFP fluorescent 
signal in the nucleus at least as high as the fluorescent signal in the cytosol. 
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[3H] Leucine incorporation assay. 24 h after serum starvation NRVMs were incubated with 
10 μmol/L NE in the presence or absence of Bay 60-7550 (10 μmol/L) for 36 h. NRVMs were 
then incubated in the same medium with 1.0 μCi/ml [3H] Leucine for an additional 12 h. The 
medium was then washed off the cells with ice-cold PBS and cells were fixed on ice for 30 
min with cold 10% TCA. After washing twice with 10% TCA and once with water, the 
radioactivity incorporated into the TCA precipitate was determined by liquid scintillation 
counting after solubilisation in 0.1 M NaOH for 10 minutes. 
FRET imaging. FRET imaging experiments were performed 24-48 h after NRVMs 
transfection with the Epac1-camps FRET sensor7. Cells were maintained at room 
temperature in a Ringer modified saline (NaCl 125 mmol/L, KCl 5 mmol/L, Na3PO4 1 mmol/L, 
MgSO4 1 mmol/L, Hepes 20 mmol/L, Glucose 5.5 mmol/L, CaCl2 1 mmol/L, pH 7.4), and 
imaged on an inverted microscope (Olympus IX71) using a PlanApoN, 60X, NA 1.42 oil 
immersion objective, 0.17/FN 26.5 (Olympus, UK). The microscope was equipped with a 
coolSNAP HQ monochrome camera system (Photometrics) and a beam-splitter optical 
device (Dual-view simultaneous-imaging system, DV2 mag biosystem, Photometrics, ET-04-
EM). The FRET filter settings used throughout were: CFP excitation filter ET436/20x, 
dichroic mirror 455DCLP (Chroma Technology) in the microscope filter cube; dichroic mirror 
505DCLP, YFP emission filter 545 nm, and CFP emission filter 480 nm (Chroma 
Technology) in the beam splitter. Images were acquired and processed using Meta imaging 
series 7.1, MetaFluor, (Molecular Devices). FRET changes were measured as changes in 
the background-subtracted 480/545 nm fluorescence emission intensity on excitation at 430 
nm and expressed as R/R0, where R is the ratio at time t and R0 is the ratio at time = 0 s. 
Value are expressed as mean ± SEM. 
Pull downs, Immunoprecipitation and Western Blot. For pull down experiments, 
Neonatal Rat Ventricular Myocytes (NRVMs) were transfected with equal amounts of NFAT-
GFP together with a plasmid expressing the potent PKA inhibitor protein Protein Kinase 
inhibitor (PKI) isoform alpha tagged with mCherry or, as control, same quantity of a plasmid 
expressing only the tag (mCherry). Twenty-four hours after transfection, cells were treated 
with NE (10µM) or NE plus Bay60-7550 (10µM) for 10 minutes. Cells were lysed using RIPA 
buffer (Sigma) complemented with protease and phosphatase inhibitor cocktail (Thermo 
Scientific). Insoluble material was removed by centrifugation at 14,000g for 10 min at 4oC 
and total protein was quantified by the Bradford method (Sigma). For the pull down 
experiments cell lysates were incubated for 2h-4h at 4oC with 25µl of agarose beads coated 
with a monoclonal anti-GFP antibody (Chromotek). Beads were washed five times with ice-
cold PBS and the proteins were released with 25µl of 2x SDS-loading buffer. For the 
immunoprecipitation experiments, 6x 106 NRVMs were plated into 10cm petri dishes coated 
with laminin. The day after cells were rinsed twice with ADS buffer and their medium 
replaced with serum free media. Cells were treated for 48h with NE (10µM), BAY60-7550 
(10µM), Rolipram (10µM) alone or their combinations. For mouse left ventricles whole cell 
lysates from frozen tissue were obtained by homogenisation in lysis buffer 
(CelLytic™ MT, C3228; Sigma) with protease (Complete Mini EDTA-free tablets; 
Roche Diagnostics) and phosphatase inhibitors PhosSTOP Phosphatase Inhibitor 
Cocktail Tablet; Roche Diagnostics) using Precellys tissue homogeniser (2 times for 
20 sec). Protein concentrations were determined by Micro BCA Protein Assay Kit 
(Pierce, Rockford, IL).1mg-2mg of total cell or tissue lysates were pre-cleared rotating for 
2h at 4oC with 25-50µl of agarose beads. After pre-clearing 2µg of anti-NFAT mouse 
monoclonal antibody (or normal mouse Igg for the control) were added to the samples and 
were allowed to incubate ON at 4 oC. The day after 20µl of agarose beads (G) were added 
and allowed to incubate for additional 2-4h at 4 oC. Afterwards beads were washed five times 
with ice-cold PBS and finally re-suspended with 25µl of 2x SDS-loading buffer. Pulled down 
or immunoprecipitated proteins were released from the beads at 95oC for 5 min and then 
were resolved on 5%-20% tris-acetate SDS/PAGE gels (Life sciences) and electro-blotted 
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onto PVDF membranes (Hybond-P, Amersham Biosciences, Piscataway, NJ). After transfer 
PVDF membranes were blocked for 1h at room temperature in 5% milk with Tris-buffered 
saline/Tween 20 (TBST; 10mM Tris HCl, PH 8.0/150mM NaCl/0.1% Tween 20). The 
membranes were incubated over night at 4 oC with the primary antibodies. After five washes 
with TBST, membranes were incubated at room temperature for 2h with appropriate 
peroxidase-conjugated secondary antibodies. Peroxidase activity was detected with 
chemiluminescence (ECL western blotting detection kit, Thermo Scientific). Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) antibody (1:2000; Santa Cruz) was used as a loading 
control for the total cell lysates and to detect protein contamination for the 
immunoprecipitated proteins, while anti-GFP or anti NFAT antibodies were used to control 
for efficient pull down and immunoprecipitation respectively. For the experiment shown in 
Suppl. Fig. 9, after preclearing, proteins were immunoprecipitated overnight at 4oC with anti-
GFP antibody and the immunocomplexes were retrieved using Protein A beads (Invitrogen). 
The immunoprecipitates were then collected by centrifugation at 13’000 rpm for 3 min and 
washed three times with lysis buffer. Bound proteins were then eluted in SDS-PAGE sample 
buffer and subjected to SDS-PAGE and immunoblotting for phospho-RXXS/T. The blots 
were stripped with stripping buffer (Thermo Scientific) and reprobed with anti-GFP antibody 
as internal controls. For the experiments shown in Fig. 7A and B, proteins were 
immunoprecipitated with anti phospho-PKA substrate (Cell Signalling) and the immunoblots 
were performed with anti-GFP antibody (Santa Cruz). Control experiments were performed 
using normal rabbit IgG (Santa Cruz). Quantification of the band intensity was accomplished 
by densitometry using Quantity One 1-D software (Bio-Rad). 
 
Luciferase assay. NFAT activation was followed by reporter assays using adenoviral 
transduction of NFAT reporter vector Ad-NFAT-Luc (Vector Biolabs). Infection efficiency of 
the adenoviral vectors was controlled by fluorescence microscopy using the mCherry 
expressing adenoviral vector Ad-mCherry (Vector Biolabs) and calculated at 90%-95%. 
Freshly isolated NRVMs were counted and equal amounts of cells were seeded in 6-well 
plates, pre-coated with laminin. The day after platting cells were washed with ADS and the 
media replaced with serum free medium. Cells were treated with Phenylephrine (PE) or left 
untreated. The next day cell media was complemented with the GSK-3 kinase inhibitor 6-
bromoindirubin-3’-oxime (BIO) (5µM) or the JNK kinase inhibitor SP6000125 (SP6) (20µM) 
(Calbiochem). Twenty-four hours after cells were lysed and luciferase expression was 
determined by using the Dual-Luciferase Reporter Assay system (Promega Corporation, WI, 
USA).   
Luciferase activity in heart tissue from NFAT-reporter mice was measured with the 
Luciferase Assay System protocol (E1000, Promega) according to the manufacturer’s 
protocol. Left ventricular myocardium was homogenized and mixed with the substrate buffer 
after normalizing for protein concentration in each homogenate. Luminescence was 
measured with a Victor3 1420 Multilabel Counter (PerkinElmer, Waltham, MA) and 
normalized to sham values. Four repeats were performed per heart, where each repeat was 
normalized to corresponding sham values. 
 
 
Statistical analysis. Data were expressed as mean ± s.e.m. Differences between multiple 
groups were compared by analysis of variance (ANOVA) followed by a Tukey’s or Dunnett’s 
multiple comparisons tests. Two-group analysis was performed by t-test. Number of 
replicates is indicated in the figure legends. *p≤0.05; **p≤ 0.01; *** p ≤ 0.005; ns= not 
significant. 
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Online Table I 
 TAC + vehicle 
 
TAC + BAY 60-7550 
TAC pressure gradient (m/s) 
 
3.2±0.1 3.2±0.1 
Left atrial diameter (LAD) (mm) 
 
2.1±0.1 2.0±0.1 
Left ventricle diameter (LVDd) (mm) 
 
4.1±0.2 4.1±0.1 
Baseline data calculated from echocardiography recordings after randomization to BAY 60 
7550 or vehicle in C57/Bl6 mice obtained at day 1 after TAC surgery. p>0.4 
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Online Table II 
 TAC + vehicle 
 
TAC + BAY 60-7550 
TAC pressure gradient (m/s) 
 
3.2±0.1 
 
2.9±0.1 
Left atrial diameter (LAD) (mm) 
 
1.8±0.04 1.9±0.1 
Left ventricle diameter (LVDd) (mm) 
 
3.3±0.1 3.2±0.2 
Baseline data calculated from echocardiography recordings after randomization to BAY 60 
7550 or vehicle in NFAT reporter mice obtained at day 1 after TAC surgery. p>0.1 
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Online Figure I.  (A) ANP mRNA levels (mean ± s.e.m of 3 independent experiments) 
measured in NRVMs treated for 48 hours with NE (10 µmol/L), or with NE (10 µmol/L) + BAY 
60-7550 (10µmol/L) as indicated. (B) Cell surface area measured for control or NRVMs 
treated with NE (10 µmol/L), or with NE (10 µmol/L) + BAY 60-7550 (50 nmol/L) (mean ± 
s.e.m of a minimum of n=71 cells per condition). (C) [3H] leucine incorporation (mean ± s.e.m 
of n ≥ 27 independent experiments) measured in NRVMs untreated or treated with NE (10 
µmol/L) or NE plus EHNA (10 µmol/L). (D) Cell size measured for cardiac myocytes isolated 
from neonatal mice and treated for 48 hours with NE (10 µmol/L) alone or in combination 
with BAY 60-7550 (10 µmol/L) as indicated (mean ± s.e.m of a minimum of n=113 cells per 
condition). Pixel size= 0.1075 µm.  (E) Cell surface area of ARVMs untreated or treated for 
24 hours with NE (1 µmol/L), or NE in combination with forskolin (1 µmol/L), cilostamide (10 
µmol/L), or BAY 60-7550 (50 nmol/L) (mean ± s.e.m of a minimum of n=17 cells per 
condition). Pixel size= 0.1613 µm. (F) ANP mRNA levels (mean ± s.e.m of a minimum of 9 
independent experiments) measured for ARVMs untreated or treated with NE (1 µmol/L) or 
NE plus BAY 60-7550 (50 nmol/L). (G) Luciferase activity relative measured in NRVMs 
treated for 48 hours with PE (10 µmol/L), BAY 60-7550 (10 µmol/L), BIO (5 µmol/L) and SP6 
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(20 µmol/L)as indicated (mean ± s.e.m of 5 independent experiments). (H) Representative 
long axis echocardiographic M-mode recordings of left ventricle in C57/Bl6 TAC mice treated 
as indicated for 3 weeks. (I) Left ventricular mass calculated by echocardiography in C57/Bl6 
TAC mice after 3 weeks with BAY 60-7550 or vehicle treatment (n=4-6 mice per group). One 
-way ANOVA and Tukey’s multiple comparison tests were utilized in all data set. * p ≤ 0.05; 
** p≤0.01; *** p≤0.005; ns= not significant.   
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Online Figure II (A) PDE2 mRNA levels in cell expressing the control siGLO Red or siPDE2 
(3’-UTR) sequences and measured by RT-PCR. (B) Representative DIC images of NE-
treated NRVMs expressing siGLO Red (left panel), siPDE2 (3’-UTR) (middle panel) or 
siPDE2 (3’-UTR) in combination with siRNA-resistant PDE2Awt-mRFP (right panel). The 
panel on the right also show, as an overlay with the DIC image, the fluorescence signal from 
PDE2Awt-mRFP. Scale bar: 10 µm. (C) Summary of cell surface area calculated for NRVMs 
treated with NE and transfected with siGLO Red, or siPDE2 (3’-UTR), or siPDE2 (3’-UTR) 
and PDE2A-mRFP (mean± s.e.m of 3 independent experiments, number of cells ≥56). t-test 
was performed in A and One-way ANOVA and Tukey’s multiple comparison test in C. Pixel 
size= 0.1075 µm.  ** p ≤0,01; *** p≤ 0,005. 
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Online Figure III. (A) Image of representative cells and (B) cell surface area measured for 
control ARVMs and ARVMs transduced in vitro with AdV5/PDE2Awt at 100 plaque forming 
unit (PFU)/cell. (C) Representative cells and (D) cell surface area calculated for 
untransduced ARVMs or ARVMs infected with AdV5/PDE2Adn (mean± s.e.m of 3 
independent experiments, number of cells ≥100). Pixel size = 0.1613 µm. Scale bar: 10 µm. 
t-test was utilised for statistical analysis. *** p≤ 0,005; ns= not significant.  
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Online Figure IV. Cell size (A) and NFAT-GFP nulcear translocation (B) calculated for 
control, NRVMs treated with NE (10 µmol/L) or with the selective PDE5 inhibitor sildenafil 
(10 nmol/L) (mean ± s.e.m of n ≥ 85 cells per conditions and of n =4 independent 
experiments respectively). One-way ANOVA and Tukey’s multiple comparison tests were 
performed. *** p≤0.005; ns= not significant. 
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Online Figure V. (A) Normalized mean kinetics of FRET change induced by isoproterenol 
(10nmol/L), BAY 60-7550 (10µmol/L) and H89 (10µmol/L) in NRVMs expressing the 
cytosolic PKA activity reporter AKAR48. (B) Normalized mean kinetics of FRET change 
induced by NE (10nmol/L), BAY 60-7550 (10µmol/L) and H89 (10µmol/L) in NRVMs 
expressing AKAR4. (C) Normalized mean kinetics measured in hypertrophied NRVMs 
(treated for 48 hours with 10µmol/L NE) expressing AKAR4 and challenged with 
isoproterenol (10nmol/L), BAY 60-7550 (10µmol/L) and H89 (10µmol/L). (D) Normalized 
mean kinetics of FRET change induced by H89 (10µmol/L) in NRVMs expressing the 
cytosolic PKA activity reporter AKAR4 and treated for 48 hours with NE (10µmol/L) or NE 
plus BAY 60-7550 (10µmol/L). n≥4; t-test was performed in D. * p≤0.05 
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Online Figure VI. To gain insight on the different subcellular localisation of individual PDEs 
we have performed immunostaining using family specific antibodies to PDEs and assessed 
the overlay of their signal with α-actinin immunostaining used as a reference for the 
sarcomeric Z line. We have used the Pearson’s correlation coefficient to estimate the degree 
of colocalisation of different PDEs with the Z line and taken a significant difference in this 
parameter as an indication of different localisation of PDEs. (A) Representative images of 
ARVMs co-stained with specific antibodies against PDE2A, PDE3A, PDE4B or PDE4D and 
anti-α-actinin antibody. (B) Co-localisation of PDE staining and α-actinin was measured as 
Pearson's correlation coefficient. One-way ANOVA and Tukey’s multiple comparison tests 
were utilised. *** p≤0.005; *p≤0.05. 
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Online Figure VII. (A) Percentage of cells showing NFAT-nuclear translocation (mean± 
s.e.m of 3 independent experiments, number of cells ≥51) for NE-treated myocytes or NE-
treated myocytes expressing PDE2Adn-mRFP. (B) NFAT-nuclear translocation 
measurements (mean± s.e.m of 3 independent experiments, number of cells ≥58) for NE-
treated NRVMs and NRVMs treated with NE and overexpressing PDE2Awt-mRFP. (C) 
Images of representative cells and (D) cell surface area of NE-treated ARVMs in the 
absence or presence of overexpressed PDE2Adn (mean± s.e.m of 3 independent 
experiments, number of cells ≥68). (E) Representative images and (F) cell surface area of 
NE-treated ARVMs in the absence or presence of overexpressed PDE2Awt (mean± s.e.m of 
3 independent experiments, number of cells ≥68). Pixel size = 0.1613 µm. Scale bar: 10 µm. 
For all experiments a t-test statistical analysis was performed. ** p ≤0.01; ns= not significant. 
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Online Figure VIII. cAMP changes detected in NRVMs by RI-epac (white bars) or by RII-
epac (black bars) upon stimulation with 10 nmol/L isoproterenol followed by addition of either 
10 µM BAY 60-7550 (A),  or of 10 µmol/L cilostamide (B) or rolipram (C); data are mean ± 
s.e.m, n≥9 cells. cAMP changes induced by 10 nmol/L isoproterenol followed by either 10 
µmol/L BAY 60-7550  (D) or of 10 µmol/L cilostamide (E) in ARVMs expressing RI-epac or 
RII-epac; data are mean ± s.e.m, n≥8 cells. For all experiments a t-test statistical analysis 
was performed. *** p≤ 0.005; ** p ≤0.01; * p ≤ 0.05; ns= not significant. 
 
 
 
 
 
 
 
 
 
 
 
17 
 
 
Online Figure IX.  (A) Representative western blot of NFAT-GFP pull down from NRVMs 
treated with NE or NE and BAY 60-7550 and probed with a PKA substrate antibody (upper 
panel, P-RXXS* signal)  and with a GFP-specific antibody (lower panel). (B) Quantification of 
the experiment shown in (A). (C) Representative image and (D) quantification of 4 
independent pull down experiments performed using an anti Phospho-PKA substrate 
antibody on lysates from NRVMs expressing NFAT-GFP, treated with NE, NE plus BAY 60-
7550 or NE plus rolipram (10 µmol/L) and probed with a GFP-specific antibody Values are 
mean± s.e.m of 3 independent experiments. 
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Online Figure X. (A) Nuclear translocation of NFAT-GFP for NRVMs treated with NE and 
overexpressing PDE2Awt-mRFP or PDE2Adn-mRFP as indicated (3 independent 
experiments, n ≥51). (B) Nuclear translocation of NFAT-GFP triple mutant calculated for 
NRVMs treated with NE and overexpressing PDE2Awt-mRFP or PDE2Adn-mRFP (3 
independent experiments, n≥48). (C) Summary of cell surface area for NE-treated NRVMs 
expressing NFAT-GFP wild type and PDE2Awt-mRFP or PDE2Adn-mRFP as indicated (3 
independent experiments, n ≥35). (D) Cell surface area of NE-treated NRVMs expressing 
NFAT-GFP triple mutant and PDE2Awt-mRFP or PDE2Adn-mRFP as indicated (3 
independent experiments, n ≥20). In C and D t-test was utilised, one-way ANOVA and 
Tukey’s multiple comparison tests were performed in A and B. Pixel size= 0.1075 µm. * p ≤ 
0.05; ** p ≤0.01; ns= not significant. 
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Online Figure XI. (A) Representative long axis echocardiographic  M-mode recordings of 
left ventricle from NFAT reporter TAC mice treated as indicated for 2 weeks. (B) Left 
ventricular mass calculated by echocardiography in NFAT reporter TAC mice after 2 weeks 
treatment with BAY 60-7550 or vehicle. (C) LVW/BW ratio values calculated post-mortem in 
NFAT reporter TAC mice after 2 weeks with BAY 60-7550 or vehicle treatment as indicated. 
One-way ANOVA and Tukey’s multiple comparison tests were performed n=5-8 mice per 
group. * p ≤ 0.05; ** p ≤0.01; *** p ≤0.001; ns= not significant.  
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Online Figure XII. ARVMs were stimulated with 10 µmol/L NE for 24 h and infected with 
adenovirus encoding for PDE2A wild type (AdV5/PDE2). Cell surface area of NE treated 
cells is expressed as percentage of their relative untreated controls (100%) as in Mehel et 
al9. t-test statistical analysis was performed. * p ≤ 0.05 
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